SEC Form 4 · accession 0001209191-17-058527
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sujal Shah
Officer — President & CEO · Director
Period of report
Oct 27, 2017
Accepted (ET)
Oct 31, 2017 · 9:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.21 | Oct 27, 2017 | A | 640,000 | A | — | Oct 26, 2027 | Common Stock | 640,000 | 640,000 | D |
Explanation of responses
- F1The shares subject to the option shall vest in 48 equal monthly installments commencing on October 27, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date.